Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Zhong-Yi DongYi-Long Wu

Abstract

Programmed cell death protein-1 (PD-1) and ligand (PD-L1) provide an important escape mechanism from immune attack, and blockade therapy of these proteins show promising clinical benefits in many types of cancer. PD-L1 can be induced by interferon-gamma (IFN-γ), hypoxia, or toll-like receptor (TLR)-mediated pathways that confer adaptive immune resistance, or upregulated by oncogenic signals leading to constitutive expression and resulting in intrinsic immune resistance. The PD-1/PD-L1 checkpoint blockade, which targets regulatory pathways in T cells to overcome immune resistance, is correlated to PD-L1 expression pattern and the presence of tumor-infiltrating lymphocytes (TILs). Meanwhile, immunogenic mutation loads show significant response to checkpoint blockade, which is probably due to PD-1/L1 status and TIL content. Finally, the clinical strategies to design effective checkpoint-targeting immunotherapies are based on the classification of inducible/constitutive expression of PD-L1 and the presence of TILs.

References

Jun 17, 2005·Cancer Research·Bo HuangHuabao Xiong
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·W Scott WebsterHaidong Dong
Nov 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andor PivarcsiBernhard Homey
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Aug 28, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Vesna PulkoHaidong Dong
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jan 27, 2011·European Journal of Immunology·Sabine J WölfleKlaus Heeg
May 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian P PollackTodd V Cartee
Dec 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James S WilmottRichard A Scolyer
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Antoni Ribas
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yuhui HuangMark C Poznansky
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennie T FrederickJennifer A Wargo
Feb 27, 2013·Cancer Research·Yuhui HuangRakesh K Jain
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jun 12, 2013·The Journal of Experimental Medicine·Rikke B HolmgaardJames P Allison
Jul 19, 2013·The Journal of Clinical Investigation·Anusha KalbasiNeha Vapiwala
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Nov 15, 2013·The Journal of Investigative Dermatology·Junpei FurutaShinji Shimada
Dec 12, 2013·Cancer Discovery·Andrew J Rech, Robert H Vonderheide
Jan 3, 2014·The Journal of Clinical Investigation·Liufu DengYang-Xin Fu
Jan 9, 2014·Hematology/oncology and Stem Cell Therapy·Sehar Afreen, Said Dermime
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geraldine O'Sullivan CoyneJames L Gulley
Apr 30, 2014·Cancer Research·Darya Alizadeh, Nicolas Larmonier
Apr 30, 2014·The Journal of Experimental Medicine·Muhammad Zaeem NomanSalem Chouaib
May 20, 2014·Cancer Immunology Research·F Stephen HodiDavid McDermott
Jul 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K AzumaI Okamoto
Jul 23, 2014·Oncoimmunology·José Medina-EcheverzPedro Berraondo

❮ Previous
Next ❯

Citations

May 6, 2016·Expert Review of Respiratory Medicine·Mariacarmela SantarpiaRafael Rosell
Mar 28, 2018·Journal of Hematology & Oncology·Rosemarie Tremblay-LeMayHong Chang
May 18, 2019·American Society of Clinical Oncology Educational Book·Charlene M FaresSiwen Hu-Lieskovan
Dec 6, 2019·Current Opinion in Obstetrics & Gynecology·Curtis D ChinJianyu Rao
Dec 8, 2019·Virchows Archiv : an International Journal of Pathology·Melissa AlameVanessa Szablewski
Nov 7, 2019·Dose-response : a Publication of International Hormesis Society·Weiqiang HuangJian Guan
Nov 21, 2017·Oncology Letters·Katarzyna JakubowskaWaldemar Famulski
Apr 19, 2017·Current Oncology Reports·Aaron C TanMustafa Khasraw
Apr 16, 2020·Cancers·Hideto TamuraKoiti Inokuchi
Dec 10, 2020·Open Biology·Milaid Granadillo RodríguezLinda Chelico
Mar 3, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Deborah B DoroshowRoy S Herbst
Nov 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tuba N GideGeorgina V Long
Jan 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhong-Yi DongYi-Long Wu
Apr 21, 2021·Clinical Lung Cancer·Luis Cabezón-GutiérrezParham Khosravi-Shahi
Jul 25, 2021·Cancers·Julien AncelValérian Dormoy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis